Key Highlights

  • Both DIAMOND Phase 3 trials missed the primary endpoint on May 29.
  • Oculis does not currently plan to file with the US FDA for DME.
  • Cash was $282.3 million at June 30, 2026.
  • Cash runway extends into the second half of 2029.

Oculis Holding AG (NASDAQ:OCS) enters the new trading week with a changed investment narrative. Earlier this year the Switzerland-based ophthalmology developer reported that its two DIAMOND Phase 3 trials of OCS-01 eye drops in diabetic macular edema (DME) did not meet their primary endpoint, and the company said it does not currently plan to file with the US FDA for that indication. That outcome shifted attention to the rest of the pipeline and to the balance sheet that funds it.

Latest Company Context

On May 29, 2026, Oculis announced topline DIAMOND results. According to the company, the primary endpoint, mean change in best-corrected visual acuity at Week 52, was not met in both trials, and the key secondary endpoint of a 15-letter gain was also missed. Retinal thickness fell versus vehicle in DIAMOND-2 at all visits, and safety was described as consistent with earlier trials. The company reported cash, equivalents and short-term investments of $278 million at March 31, 2026, with runway into the second half of 2029.

Per a third-party summary of its Q2 report dated August 6, 2026, Oculis held $282.3 million at June 30, 2026, versus $268.7 million at year-end 2025, as share sales more than offset operating costs. First-half net loss was reported at $49.3 million, compared with $67.9 million a year earlier, helped by a fair-value gain on warrant liabilities and foreign exchange. Research and development expense was $19.3 million in the second quarter and G&A was $10.9 million. These figures are from a summary source and may be checked against the company's filings.

Key Business Drivers

With OCS-01 in DME no longer a filing candidate, the pipeline now leans on two assets. Privosegtor, a neuroprotective candidate, is in the PIONEER registrational programme for optic neuropathies such as optic neuritis and non-arteritic anterior ischemic optic neuropathy. The company has also reported positive FDA feedback on expanding into acute multiple sclerosis relapses. Licaminlimab, a TNF inhibitor for dry eye disease, is in the genotype-guided PREDICT-1 registrational trial, where enrolment reportedly exceeded 45% with all sites activated.

The financial driver is runway. A balance sheet that management says can fund operations into the second half of 2029 could give the company time to execute, though clinical development carries binary risk. Operating expenses are rising, with G&A up year over year, and further equity raising remains a possibility common to the sector.

What Investors Should Watch

Investors may watch several identifiable milestones. The company has planned an IND submission for privosegtor in acute MS relapses in the fourth quarter of 2026. Topline results from the licaminlimab PREDICT-1 trial are expected around year-end 2026, which could be an important data point for the dry eye programme. Progress and any timeline updates for the PIONEER-1 trial may also matter.

Beyond clinical events, the next quarterly report could show whether cash burn tracks expectations and whether the runway guidance holds. Investors may also monitor any strategic commentary on whether OCS-01 could be pursued in other indications, and any financing or partnership announcements. Management guidance on timing is not a guarantee, and trial schedules can shift.

A Setback Shifts Attention to the Pipeline and the Runway

Oculis has turned from a single-program story into a pipeline-catalyst story after DIAMOND. The questions now are how far the remaining programmes progress and how long cash lasts, with runway into the second half of 2029.